GlaxoSmithKline plc (GSK) Earns Neutral Rating from J P Morgan Chase & Co
GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating reissued by investment analysts at J P Morgan Chase & Co in a research note issued on Monday.
GSK has been the subject of several other research reports. Liberum Capital reduced their price objective on shares of GlaxoSmithKline plc from GBX 1,900 ($25.25) to GBX 1,760 ($23.39) and set a “buy” rating for the company in a research note on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.25) target price on shares of GlaxoSmithKline plc and gave the stock a “buy” rating in a research report on Wednesday, July 26th. BNP Paribas set a GBX 1,620 ($21.53) target price on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research report on Wednesday, September 6th. Barclays PLC restated an “equal weight” rating and set a GBX 1,550 ($20.60) target price on shares of GlaxoSmithKline plc in a research report on Thursday, July 27th. Finally, Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Wednesday, September 20th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,683.50 ($22.37).
GlaxoSmithKline plc (GSK) opened at 1522.00 on Monday. GlaxoSmithKline plc has a 52-week low of GBX 1,444.00 and a 52-week high of GBX 1,724.50. The firm’s market cap is GBX 74.40 billion. The company’s 50 day moving average is GBX 1,502.15 and its 200 day moving average is GBX 1,580.48.
COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/23/glaxosmithkline-plc-gsk-earns-neutral-rating-from-j-p-morgan-chase-co.html.
In other news, insider Simon Dingemans bought 1,076 shares of the business’s stock in a transaction on Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.29) per share, for a total transaction of £16,430.52 ($21,831.68). Also, insider Manvinder Singh Banga bought 2,267 shares of the business’s stock in a transaction on Wednesday, July 26th. The stock was purchased at an average price of GBX 1,599 ($21.25) per share, for a total transaction of £36,249.33 ($48,165.47). Insiders acquired a total of 3,368 shares of company stock worth $5,305,807 in the last 90 days.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.